Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,043 public trials 577 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Recruiting

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

NCT07589634

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital Ampang Ampang, Malaysia
  • Beverly Hills Cancer Center (BHCC) Beverly Hills, California, United States
  • Hospital Sultanah Aminah Johor Bharu, Malaysia
  • Sarawak General Hospital Kuching, Malaysia
View Trial Details
Recruiting

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

NCT07681596

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Denver, Colorado, United States
  • Research Site Tampa, Florida, United States
  • Research Site Atlanta, Georgia, United States
View Trial Details
Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606

Conditions
B-cell Non Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +21 more
Locations
  • Start Cala Los Angeles, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • NYU Langone New York, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
View all 29 locations
View Trial Details
Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Los Alamitos, California, United States
  • GSK Investigational Site Torrance, California, United States
  • GSK Investigational Site Whittier, California, United States
  • GSK Investigational Site Fort Myers, Florida, United States
View all 59 locations
View Trial Details
Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Infirmary Cancer Care Mobile, Alabama, United States
  • Western Regional Medical Center, Inc. dba. City of Hope Phoenix Goodyear, Arizona, United States
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • Clovis Community Medical Center Clovis, California, United States
View all 270 locations
View Trial Details
Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Clovis Community Medical Center Clovis, California, United States
  • Community Regional Medical Center Fresno, California, United States
  • UCHealth Poudre Valley Hospital Fort Collins, Colorado, United States
  • UCHealth Greeley Hospital Greeley, Colorado, United States
View all 237 locations
View Trial Details

Related conditions